FDA approves groundbreaking pancreatic cancer drug

The Food and Drug Administration recently granted approval for a groundbreaking new drug aimed at treating advanced pancreatic cancer, providing U.S. patients with a more effective treatment option against one of the deadliest types of cancer. The FDA gave expedited approval to the first-of-its-kind pill, daraxonrasib, which targets a mutated protein fueling tumor growth in over 90% of pancreatic cancer cases.

The daily pills, sold under the brand name Rasonque by Revolution Medicines, nearly doubled the median survival time of patients, with fewer severe side effects compared to chemotherapy. The company-funded study enrolled 500 patients whose metastatic, or spreading, cancer had stopped responding to prior treatment, resulting in a median survival of 13.2 months for those taking the new treatment, compared to 6.7 months for those receiving chemotherapy.

Side effects included skin rash, mouth sores, diarrhea, and other digestive issues. Dr. Pashtoon Kasi of City of Hope Orange County emphasized that while the drug is not a cure, it represents the best option available for these patients. Pancreatic cancer remains highly lethal due to its difficulty in detection before spreading to other organs, with an estimated 67,000 new cases diagnosed and over 52,000 deaths in the United States annually.

The five-year overall survival rate stands at 13%. Revolution Medicines' innovative drug targets mutations in the RAS gene family, specifically KRAS mutations, which are crucial in driving pancreatic cancer. The drug's unique approach of using a molecular glue to bind with multiple KRAS subtypes overcomes the long-standing challenge of making "undruggable" cancer drivers effective.

The drug's approval came more than six months ahead of schedule, with FDA regulators highlighting their commitment to delivering more cures and meaningful treatments to patients as quickly as possible.